SZSheng Zhang

Sheng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sheng Zhang has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 2 December 2025
      • Vol. 8
    Open Access

    Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies

    by Ren Wang, Yuanhang Chen, Liping Li, Lun Zhang, Sheng Zhang

    Non-small-cell lung cancer (NSCLC) remains the leading cause of global cancer-related mortality. NSCLC patients with epidermal growth factor receptor (EGFR) mutations benefit substantially from treatment with EGFR tyrosine kinase inhibitors, particularly osimertinib. Although recent clinical trials have established osimertinib as effective treatment across many stages of EGFR-mutant NSCLC, the inevitable emergence of acquired resistance poses a major therapeutic challenge despite the substantial clinical benefit. Understanding the mechanisms of osimertinib acquired resistance is urgently needed to identify effective strategies to overcome it. Resistance to osimertinib including on-target mechanisms such as novel EGFR secondary mutation, off-target mechanisms such as mesenchymal-epithelial transition or human EGFR 2 amplification, mutations in downstream signaling molecules, and oncogenic fusions, and the Histological transformations (such as epithelial-mesenchymal transition, squamous cell carcinoma, or small cell lung cancer) have been well described. This review summarizes the mechanisms and clinical significance of osimertinib-acquired resistance in recent years, as well as new clinical treatments. It is expected to provide valuable insights and potential new strategies for the clinical treatment of EGFR-mutated NSCLC patients with osimertinib resistance.


  • Open Access

    Recent advances in extracellular matrix manipulation for kidney organoid research

    by Ren Wang, Yufei Sui, Qiuyan Liu, Yucui Xiong, Shanshan Li, Wu Guo, Yiwei Xu, Sheng Zhang

    The kidney plays a crucial role in maintaining the body’s microenvironment homeostasis. However, current treatment options and therapeutic agents for chronic kidney disease (CKD) are limited. Fortunately, the advent of kidney organoids has introduced a novel in vitro model for studying kidney diseases and drug screening. Despite significant efforts has been leveraged to mimic the spatial-temporal dynamics of fetal renal development in various types of kidney organoids, there is still a discrepancy in cell types and maturity compared to native kidney tissue. The extracellular matrix (ECM) plays a crucial role in regulating cellular signaling, which ultimately affects cell fate decision. As a result, ECM can refine the microenvironment of organoids, promoting their efficient differentiation and maturation. This review examines the existing techniques for culturing kidney organoids, evaluates the strengths and weaknesses of various types of kidney organoids, and assesses the advancements and limitations associated with the utilization of the ECM in kidney organoid culture. Additionally, it presents a discussion on constructing specific physiological and pathological microenvironments using decellularized extracellular matrix during certain developmental stages or disease occurrences, aiding the development of kidney organoids and disease models.


  • Open Access

    Recent progress of exosomal lncRNA/circRNA–miRNA–mRNA axis in lung cancer: implication for clinical application

    by Ren Wang, Yiwei Xu, Liangjing Tong, Xiao Zhang, Sheng Zhang

    Lung cancer is the leading cause of death among malignant tumors in the world. High lung cancer mortality rate is due to most of patients diagnosed at advanced stage. The Liquid biopsy of lung cancer have received recent interest for early diagnosis. One of the components of liquid biopsy is the exosome. The exosome cargos non-coding-RNAs, especially long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs). The lung cancer derived exosomal non-coding RNAs play the pivotal roles of lung cancer in carcinogenesis, diagnosis, therapy, drug resistance and prognosis of lung cancer. Given ceRNA (competitive endogenous RNA) mechanism, lncRNA or circRNA can act as ceRNA to compete to bind miRNAs and alter the expression of the targeted mRNA, contributing to the development and progression of lung cancer. The current research progress of the roles of the exosomal non-coding-RNAs and the interplay of ceRNAs and miRNAs in mediated lung cancer is illustrated in this article. Hence, we presented an experimentally validated lung cancer derived exosomal non-coding RNAs-regulated target gene axis from already existed evidence in lung cancer. Then LncRNA/circRNA-miRNA-mRNA axis may be a potential target for lung cancer treatment and has great potential in the diagnosis and prognosis of lung cancer.


  • Hormonal regulation changes in shrimp infected with Enterocytozoon hepatopenaei: a transcriptomic analysis

    by Leiting Zhang, Sheng Zhang, Yabin Dou, Hui Shen, Yi Qiao, Xiaohui Cao, Xianping Fan, Yadong Hu, Jin Qian


  • Open Access

    Comparison of miRNA transcriptome of exosomes in three categories of somatic cells with derived iPSCs

    by Chunlai Yu, Mei Zhang, Yucui Xiong, Qizheng Wang, Yuanhua Wang, Shaoling Wu, Sajjad Hussain, Yan Wang, Zhizhong Zhang, Nini Rao, et al.

    Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) through epigenetic manipulation. While the essential role of miRNA in reprogramming and maintaining pluripotency is well studied, little is known about the functions of miRNA from exosomes in this context. To fill this research gap,we comprehensively obtained the 17 sets of cellular mRNA transcriptomic data with 3.93 × 1010 bp raw reads and 18 sets of exosomal miRNA transcriptomic data with 2.83 × 107 bp raw reads from three categories of human somatic cells: peripheral blood mononuclear cells (PBMCs), skin fibroblasts(SFs) and urine cells (UCs), along with their derived iPSCs. Additionally, differentially expressed molecules of each category were identified and used to perform gene set enrichment analysis. Our study provides sets of comparative transcriptomic data of cellular mRNA and exosomal miRNA from three categories of human tissue with three individual biological controls in studies of iPSCs generation, which will contribute to a better understanding of donor cell variation in functional epigenetic regulation and differentiation bias in iPSCs.


  • Open Access

    Supplementary Methods and Supplementar Figures S1-S13 from Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

    by Livia Elena Sima, Bakhtiyor Yakubov, Sheng Zhang, Salvatore Condello, Arabela A. Grigorescu, Nkechiyere G. Nwani, Lan Chen, Gary E. Schiltz, Constandina Arvanitis, Zhong-Yin Zhang, et al.

    Materials, methods; Figure S1. 1H NMR spectrum of MT-1; Figure S2. 1H NMR spectrum of MT-2; Figure S3. 1H NMR spectrum of MT-3; Figure S4. 1H NMR spectrum of MT-4; Figure S5. 1H NMR spectrum of MT-5; Figure S6. 1H NMR spectrum of MT-6; Figure S7. Enthalpy kinetics of MT-4 -TG2 interaction as measured by Isothermal Titration Calorimetry (ITC); Figure S8. Effects of TG-53 and MT-4 on TGase activity; Figure S9. TIRF analysis of β1 integrin receptors distribution upon cell treatment with SMIs at the indicated concentrations and adhesion onto FN coated plates; Figure S10. Flow cytometry analysis of integrin β1 plasma membrane expression; Figure S11. Dose response effects induced by TG2-FN inhibitors on FAK phosphorylation; Figure S12. Experimental design for in vivo assay testing the activity of MT4; Figure S13. Cell cycle distribution and apoptosis of OVCAR5 cells primed with MT-4 or TG53 for 72 hours before treatment with paclitaxel (PTX).

  • Open Access

    Supplementary Methods and Supplementar Figures S1-S13 from Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

    by Livia Elena Sima, Bakhtiyor Yakubov, Sheng Zhang, Salvatore Condello, Arabela A. Grigorescu, Nkechiyere G. Nwani, Lan Chen, Gary E. Schiltz, Constandina Arvanitis, Zhong-Yin Zhang, et al.

  • Open Access

    Cerebral blood flow evaluation of intensive rosuvastatin therapy in stroke/transient ischemic attack patients with intracranial arterial atherosclerotic stenosis study: Rationale and design

    by Xuting Zhang, Ying Zhou, Sheng Zhang, Wenhong Ding, Min Lou

    Introduction: The risk of recurrent stroke is high in patients with intracranial atherosclerotic stenosis (ICAS). Statin use has been demonstrated to decrease the incidence of stroke by reducing atherosclerotic plaque burden. However, its effect on the hemodynamic situation and cerebral perfusion status has not yet been validated. With the use of computed tomography perfusion (CTP), we aim to evaluate the impact of Rosuvastatin on cerebral hemodynamic changes, as well as the downstream perfusion.Method: Cerebral bood flow evaluation of intensive rosuvastatin therapy in patients with intracranial arterial atherosclerotic stenosis (CEIRIS) is a single‐center, prospective, randomized, parallel‐group, and open‐label trial, and it will include 50 participants as estimated. Patients with moderate to severe (50%–99%) ICAS are randomized 1:1 to 10 mg/day or 20 mg/day Rosuvastatin and followed every 13 weeks until 52 weeks. The primary outcome for the trial is the change in the relative regional cerebral blood flow evaluated by CTP after 52 weeks of Rosuvastatin treatment. The secondary outcomes are cerebral blood volume, change in the degree of stenosis of the target vessel and lipid parameters.Conclusion: The CEIRIS trial about the effects of statin on the temporal hemodynamic progression of ICAS may extend our understanding of the basic pathophysiology and mechanisms of stroke in ICAS patients.


  • Open Access

    Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

    by Chengcheng Gong, Yannan Zhao, Biyun Wang, Xichun Hu, Zhonghua Wang, Jian Zhang, Sheng Zhang

    Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study


  • [Effect of pre-transplant donor specific antibody on antibody-mediated rejection and graft dysfunction].

    by Ning Wang, Wei Li, Sheng Zhang

    To explore the effect of pre-transplant donor specific antibody (DSA) on antibody-mediated rejection (AMR) and function of transplanted kidney. A total of 88 cases of renal transplant recipients were selected. Before surgery, DSA was examined by Luminex liquid phase chip in renal transplant recipients. The recipients were divided into a DSA positive group (n=20) and a DSA negative group (n=68). The follow-up time was 2 years. After the operation, the pathologic morphology of the transplanted kidney was evaluated and classified according to the Banff 2005 standard. The situation for the transplanted kidney was evaluated. The incidence of AMR in the DSA positive group and negative group was 20% and 1.5%, respectively, with significant difference between them (P0.05). The detection of DSA level before renal transplantation can predict the risk of AMR and the function of transplanted kidney. The MFI intercept point of the highest DSA (MFI> 7909.5) can be used to predict the risk of AMR.